A-Labs Capital IV Corp.
(A Capital Pool Company)

Condensed Interim Financial Statements

(Expressed in Canadian Dollars)

(Unaudited)

For the Three Months Ended June 30, 2022 and 2021

Notice to Reader

These unaudited condensed interim financial statements of A-Labs Capital IV Corp. (the “Company”) for the three months ended June 30, 2022 have been prepared by and are the responsibility of management.

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that these unaudited condensed interim financial statements have not been reviewed by its auditor.

A-Labs Capital IV Corp.

Condensed Interim Statement of Financial Position
(Expressed in Canadian Dollars)
(unaudited)

		June 30, 2022		March 31, 2022
Assets				
Current				
Cash and cash equivalents (Note 4)	**$**	**95,476**	$	101,238
	$	**95,476**	$	101,238
Liabilities				
Current				
Accounts payable and accrued liabilities	**$**	**22,372**	$	11,877
		22,372		11,877
Shareholders' Equity				
Capital stock (Note 5)		**239,118**		239,118
Contributed surplus		**29,823**		29,823
Deficit		**(195,837)**		(179,580)
		73,104		89,361
	$	**95,476**	$	101,238

Nature of Operations (Note 1)

Approved by the Board

"(signed) Chay Benhamou"
Director

"(signed) Yossi Shemesh"
Director

A-Labs Capital IV Corp.

Condensed Interim Statement of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

(Unaudited)

	For the Three Month Period Ended June 30, 2022	For The Three Month Period Ended June 30, 2021
Expenses		
Operating expenses	**$ 6,365**	$ 6,967
Professional fees	**9,892**	2,179
Total expenses	**(16,257)**	(9,146)
Net loss and comprehensive loss for the period	**$ (16,257)**	$ (9,146)
Basic and diluted loss for the period (Note 5)	**$ (0.008)**	$ (0.005)
Weighted average number of shares outstanding (Note 5)	**2,000,000**	2,000,000

A-Labs Capital IV Corp.

Condensed Interim Statement of Changes in Shareholders' Equity (Deficiency)

(Expressed in Canadian Dollars)

(Unaudited)

	Number of Shares	Amount	Contributed Surplus	Deficit	Total
Balance, March 31, **2022**	4,000,000	$ 239,118	$ 29,823	$ (179,580)	$ 89,361
Net loss for the period	-	-	-	(16,257)	(16,257)
Balance, June 30, 2022	**4,000,000**	**$ 239,118**	29,823	**(193,837)**	**$ 73,104**
Balance, March 31, **2021**	**4,000,000**	**$ 239,118**	**$ 40,384**	**$ (114,060)**	**$ 165,442**
Net loss for the period	-	-	-	(9,146)	(9,146)
Balance, June 30, 2021	**4,000,000**	**$ 239,118**	**$ 40,384**	**$ (123,206)**	**$ 156,296**

A-Labs Capital IV Corp.
Condensed Interim Statement of Cash Flows
(Expressed in Canadian Dollars)
(Unaudited)

	For the Three Month Period Ended June 30, 2022	For the Three Month Period Ended June 30, 2021
Cash provided by (used in)		
Operating Activities		
Net loss for the period	**$ (16,257)**	$ (9,146)
Changes in non-cash working capital items:		
Accounts payable and accrued liabilities	**10,495**	570
Cash (used in) operating activities	**(5,762)**	(8,576)
Net change in cash	**(5,762)**	(8,576)
Cash, beginning of period	**101,238**	173,154
Cash, end of period	**$ 95,476**	$ 164,578

~~(unaudited)~~

1. NATURE OF OPERATIONS

A-Labs Capital IV Corp. (the "Company") was incorporated by a Certificate of Incorporation issued pursuant to the provisions of the Business Corporations Act (BC) on November 26, 2018. The registered office is located at 2800 Park Place, 666 Burrard Street, Vancouver, BC, V6C 2Z7.

The Company is classified as a Capital Pool Company ("CPC") as defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The principal business of the Company will be to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction, by exercising of an option or by any concomitant transaction. The purpose of such an acquisition is to satisfy the related conditions of a Qualifying Transaction under the Exchange rules.

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process offorced liquidation. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations.

As a CPC, the Company's principal business will be the identification and evaluation of assets, properties or businesses with a view to acquisition or participation therein subject, in certain cases, to shareholder approval and acceptance by the Exchange. Where an acquisition or participation is warranted (the "Qualifying Transaction"), additional funding may be required. The ability of the Company to fund its potential future operations and commitments is dependent upon the ability of the Company to obtain additional financing.

On March 15, 2022 the Company entered into a letter of intent with Nanomedic Technologies Ltd. ("Nanomedic"). Completion of the transaction is conditional upon the completion of a private placement of securities of Nanomedic, concurrent with (or prior to) the completion of the transaction, resulting in minimum proceeds to Nanomedic of USD 15 million. The structure of the transaction shall be determined by the parties.

2. BASIS OF PRESENTATION

Statement of Compliance

These unaudited condensed interim financial statements have been prepared in accordance and compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Reporting Interpretations Committee, and IAS 34, Interim Financial Reporting.

These unaudited condensed interim financial statements should be read in conjunction with the Company's annual financial statements for the year ended March 31, 2022. The accounting policies adopted in these condensed interim financial statements are consistent with those disclosed in the Company's audited financial statements for the year ended March 31, 2022.

These condensed interim financial statements were authorized for issuance by the Board of Directors on September 7, 2022.

~~(unaudited)~~

2. BASIS OF PRESENTATION (Cont'd)

Basis of Measurement

These condensed interim financial statements are presented in Canadian dollars, which is the Company's functional and presentation currency.

Significant Accounting Judgments, Estimates and Assumptions

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities. The estimates and associated assumptions are based on anticipations and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

3. CASH RESTRICTION

The proceeds raised from the issuance of share capital may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than $3,000 per month may be used for general and administrative expenses ofthe Company. These restrictions may apply until completion of the Qualifying Transaction by the Company as pursuant to the policies of the Exchange.

4. CAPITAL STOCK

Authorized

Unlimited number of common voting shares without nominal or par value.

Issued Common Shares

Issued share capital is as follows:

Shares issued for cash	-	4,000,000
Balance, March 31, 2022 and June 30, 2022	-	4,000,000

~~(unaudited)~~

5. CAPITAL STOCK (Cont'd)

The issued and outstanding founders' common shares are subject to a CPC Escrow Agreement. Under the CPC Escrow Agreement, 10% of the escrowed common shares will be released from escrow on the issuance of the Final Exchange Bulletin (the "Initial Release") and an additional 15% will be released on the dates 6, 12, 18, 24, 30 and 36 months following the Initial Release. All common shares acquired on the exercise of stock options granted to directors, officers and non-employees prior to the completion of a qualifying transaction must also be deposited in escrow until the Final Exchange Bulletin is issued. In addition, all common shares of the Company acquired in the secondary market prior to the completion of a qualifying transaction by any person or company who becomes a control person are required to be deposited in escrow. Subject to certain exemptions permitted by the Exchange, all securities of the Company held by principals of the resulting issuer will also be escrowed. The founders' shares were deposited into escrow on July 19, 2019. Therefore, the weighted average shares outstanding does not include these shares as they are contingently returnable Loss Per Share

The calculation of basic and diluted loss per share for the three month period ended March 31, 2022 was basedon the loss attributable to common shareholders of $16,257 (2021 - $9,146) and the weighted average number of shares outstanding of 2,000,000 (2021 - 2,000,000).

6. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders.

The Company includes share capital in the definition of capital.

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

The Company is not subject to externally imposed capital requirements other than the cash restriction disclosed in Note 4.

Risk Disclosures and Fair Values

The Company's financial instruments, consisting of accrued liabilities, approximate fair values due to the relatively short term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

As at June 30, 2022, the Company had accounts payable and accrued liabilities of $22,372 and had cash of $95,476 to meet its current obligations. As a result, the Company has minimal liquidity risk.